AIRFLO supports therapeutic potential of ziresovir for RSV in infants, young children
20 Dec 2024
byAudrey Abella
In the AIRFLO study, treatment with ziresovir – a potent, selective, orally administered RSV F protein inhibitor – leads to a greater resolution of signs and symptoms of bronchiolitis in hospitalized infants and young children with respiratory syncytial virus (RSV) infection.
AIRFLO supports therapeutic potential of ziresovir for RSV in infants, young children
20 Dec 2024